152 related articles for article (PubMed ID: 36259863)
1. Imiquimod-induced hypertrophic lupus erythematosus-like reaction.
Safadi MG; Hassan S; Patel V; Viglione M; Zahner SL
Dermatol Online J; 2022 Aug; 28(4):. PubMed ID: 36259863
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod-induced subacute cutaneous lupus erythematosus-like changes.
Maguiness SM; Farsani TT; Zedek DC; Berger TG
Cutis; 2015 Jun; 95(6):349-51. PubMed ID: 26125212
[TBL] [Abstract][Full Text] [Related]
3. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
[TBL] [Abstract][Full Text] [Related]
5. Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses.
Burnett TJ; English JC; Ferris LK
J Drugs Dermatol; 2010 Aug; 9(8):1022-4. PubMed ID: 20684157
[TBL] [Abstract][Full Text] [Related]
6. Mucosal side effects in patients treated with topical imiquimod-A scoping review of the literature.
Hammerl V; Parlar B; Navarini A; Gantenbein L; Väth H; Mueller SM
Dermatol Ther; 2021 Jan; 34(1):e14355. PubMed ID: 32990395
[TBL] [Abstract][Full Text] [Related]
7. Beyond a decade of 5% imiquimod topical therapy.
A Gaspari A; Tyring SK; Rosen T
J Drugs Dermatol; 2009 May; 8(5):467-74. PubMed ID: 19537370
[TBL] [Abstract][Full Text] [Related]
8. Viral and nonviral uses of imiquimod: a review.
Gupta AK; Cherman AM; Tyring SK
J Cutan Med Surg; 2004; 8(5):338-52. PubMed ID: 15868314
[TBL] [Abstract][Full Text] [Related]
9. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
11. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
Wagstaff AJ; Perry CM
Drugs; 2007; 67(15):2187-210. PubMed ID: 17927284
[TBL] [Abstract][Full Text] [Related]
12. Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases.
Chan MP; Zimarowski MJ
Am J Dermatopathol; 2011 Jul; 33(5):523-7. PubMed ID: 21478730
[TBL] [Abstract][Full Text] [Related]
13. Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.
Badavanis G; Pasmatzi E; Monastirli A; Georgiou S; Tsambaos D
Acta Dermatovenerol Croat; 2017 Jul; 25(2):164-166. PubMed ID: 28871935
[TBL] [Abstract][Full Text] [Related]
14. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
15. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.
Papakostas D; Stockfleth E
Future Oncol; 2015 Nov; 11(22):2985-90. PubMed ID: 26450707
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation by imiquimod in patients with high-risk primary melanoma.
Narayan R; Nguyen H; Bentow JJ; Moy L; Lee DK; Greger S; Haskell J; Vanchinathan V; Chang PL; Tsui S; Konishi T; Comin-Anduix B; Dauphine C; Vargas HI; Economou JS; Ribas A; Bruhn KW; Craft N
J Invest Dermatol; 2012 Jan; 132(1):163-9. PubMed ID: 21850019
[TBL] [Abstract][Full Text] [Related]
17. Local reactions to imiquimod in the treatment of basal cell carcinoma.
Tandon Y; Brodell RT
Dermatol Online J; 2012 Sep; 18(9):1. PubMed ID: 23031368
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous horn arising from an area of discoid lupus erythematosus on the scalp.
Fatani MI; Hussain WM; Baltow B; Alsharif S
BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24700037
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod in basal cell carcinoma: how does it work?
Dummer R; Urosevic M; Kempf W; Hoek K; Hafner J; Burg G
Br J Dermatol; 2003 Nov; 149 Suppl 66():57-8. PubMed ID: 14616353
[TBL] [Abstract][Full Text] [Related]
20. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus.
Yokogawa M; Takaishi M; Nakajima K; Kamijima R; Fujimoto C; Kataoka S; Terada Y; Sano S
Arthritis Rheumatol; 2014 Mar; 66(3):694-706. PubMed ID: 24574230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
